trending Market Intelligence /marketintelligence/en/news-insights/trending/hR9ZwsDC-aJSnjDh1U-bdg2 content esgSubNav
In This List

US FDA approves Eli Lilly, Boehringer Ingelheim's type 2 diabetes drug

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


US FDA approves Eli Lilly, Boehringer Ingelheim's type 2 diabetes drug

The U.S. FDA approved Eli Lilly & Co. and Boehringer Ingelheim's Synjardy XR for adults with type 2 diabetes.

Synjardy XR is a combination of two drugs formulated to be taken once a day. The approval was based on clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea in the treatment of adults with type 2 diabetes.

The drug is co-marketed by Eli Lilly and Boehringer Ingelheim. Synjardy XR is the eighth FDA-approved treatment from Eli Lilly and Boehringer's partnership.